FMS Valuation

Fresenius Medical Care AG

Add to Watchlist

Advanced Chart

25.640

+0.34(1.344%)1D

Overview
Forecast
Valuation
Earnings

FMS Relative Valuation

FMS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, FMS is overvalued; if below, it's undervalued.

Historical Valuation

Fresenius Medical Care AG (FMS) is now in the Undervalued zone, suggesting that its current forward PE ratio of 11.00 is considered Undervalued compared with the five-year average of 14.41. The fair price of Fresenius Medical Care AG (FMS) is between 34.60 to 47.87 according to relative valuation methord. Compared to the current price of 25.64 USD , Fresenius Medical Care AG is Undervalued By 25.9%.

Relative Value

Fair Zone

34.60-47.87

Current Price：25.64

25.9%

Undervalued

11.00

Trailing

Forward

6.14

EV/EBITDA

Fresenius Medical Care AG. (FMS) has a current EV/EBITDA of 6.14. The 5-year average EV/EBITDA is 7.73. The thresholds are as follows: Strongly Undervalued below 5.73, Undervalued between 5.73 and 6.73, Fairly Valued between 8.72 and 6.73, Overvalued between 8.72 and 9.72, and Strongly Overvalued above 9.72. The current Forward EV/EBITDA of 6.14 falls within the Undervalued range.

10.83

EV/EBIT

Fresenius Medical Care AG. (FMS) has a current EV/EBIT of 10.83. The 5-year average EV/EBIT is 14.44. The thresholds are as follows: Strongly Undervalued below 9.72, Undervalued between 9.72 and 12.08, Fairly Valued between 16.80 and 12.08, Overvalued between 16.80 and 19.16, and Strongly Overvalued above 19.16. The current Forward EV/EBIT of 10.83 falls within the Undervalued range.

0.63

Fresenius Medical Care AG. (FMS) has a current PS of 0.63. The 5-year average PS is 0.73. The thresholds are as follows: Strongly Undervalued below 0.28, Undervalued between 0.28 and 0.51, Fairly Valued between 0.95 and 0.51, Overvalued between 0.95 and 1.18, and Strongly Overvalued above 1.18. The current Forward PS of 0.63 falls within the Historic Trend Line -Fairly Valued range.

4.89

P/OCF

Fresenius Medical Care AG. (FMS) has a current P/OCF of 4.89. The 5-year average P/OCF is 5.54. The thresholds are as follows: Strongly Undervalued below 2.81, Undervalued between 2.81 and 4.18, Fairly Valued between 6.91 and 4.18, Overvalued between 6.91 and 8.27, and Strongly Overvalued above 8.27. The current Forward P/OCF of 4.89 falls within the Historic Trend Line -Fairly Valued range.

7.96

P/FCF

Fresenius Medical Care AG. (FMS) has a current P/FCF of 7.96. The 5-year average P/FCF is 8.91. The thresholds are as follows: Strongly Undervalued below 2.96, Undervalued between 2.96 and 5.94, Fairly Valued between 11.88 and 5.94, Overvalued between 11.88 and 14.85, and Strongly Overvalued above 14.85. The current Forward P/FCF of 7.96 falls within the Historic Trend Line -Fairly Valued range.

Fresenius Medical Care AG (FMS) has a current Price-to-Book (P/B) ratio of 0.96. Compared to its 3-year average P/B ratio of 0.73 , the current P/B ratio is approximately 30.96% higher. Relative to its 5-year average P/B ratio of 1.02, the current P/B ratio is about -6.06% higher. Fresenius Medical Care AG (FMS) has a Forward Free Cash Flow (FCF) yield of approximately 16.30%. Compared to its 3-year average FCF yield of 14.61%, the current FCF yield is approximately 11.56% lower. Relative to its 5-year average FCF yield of 13.66% , the current FCF yield is about 19.30% lower.

0.96

P/B

Median3y

0.73

Median5y

1.02

16.30

FCF Yield

Median3y

14.61

Median5y

13.66

Competitors Valuation Multiple

The average P/S ratio for FMS's competitors is 1.34, providing a benchmark for relative valuation. Fresenius Medical Care AG Corp (FMS) exhibits a P/S ratio of 0.63, which is -52.77% above the industry average. Given its robust revenue growth of 5.84%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

FMS.N

Fresenius Medical Care AG

Encompass Health Corp

Hims & Hers Health Inc

Performance Decomposition

Market capitalization of FMS increased by 18.78% over the past 1 year. The primary factor behind the change was an increase in Margin Expansion from 5.04 to 5.68.

The secondary factor is the Revenue Growth, contributed 5.84%to the performance.

Overall, the performance of FMS in the past 1 year is driven by Margin Expansion. Which is more sustainable.

5.84%

5.13B → 5.43B

Revenue Growth

12.70%

5.04 → 5.68

Margin Expansion

0.24%

19.35 → 19.40

P/E Change

18.78%